One-on-One with Medivation CEO David Hung

Medivation's David Hung.

The story of Medivation Inc. could belong in the collection of biotech’s greatest comebacks. The San Francisco company (NASDAQ: MDVN), partner Pfizer Inc. (NYSE: PFE) and investors pinned many of their hopes on Dimebon, but even before that drug failed, Medivation was working on what now is called Xtandi in prostate cancer. I spoke with Medivation President and CEO David Hung about Xtandi, the competition in the prostate cancer drug arena, Medivation’s pipeline and the likelihood of bringing Dimebon back as an Alzheimer's-fighting drug.